FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965017201> ?p ?o ?g. }

• W1965017201 abstract "Abstract Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response. Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2. Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy. Methods We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab, nab-paclitaxel and carboplatin combination therapy (BrUOG BR-211B (NCT00617942)). Tumor core biopsies were taken before initiation of treatment and 9–13 days after patients received run-in doses of either single agent trastuzumab or nab-paclitaxel. The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression. Patients then received 18 weeks of treatment, followed by surgery to assess pathologic response to the neoadjuvant regimen. Results A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies. Of 20 evaluable patients, 10 cases who achieved a pathologic complete response (pathCR) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR (p = 0.0021). Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups. In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure. Conclusions High levels of HER2 are associated with achievement of a pathCR in the preoperative setting, while levels of Phospho-HER2 were not predictive of response. This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting. Further validation in larger cohorts is required, but this pilot data shows the feasibility of this approach." @default.
• W1965017201 created "2016-06-24" @default.
• W1965017201 creator A5002120924 @default.
• W1965017201 creator A5011363732 @default.
• W1965017201 creator A5019302956 @default.
• W1965017201 creator A5021504145 @default.
• W1965017201 creator A5021514634 @default.
• W1965017201 creator A5027326018 @default.
• W1965017201 creator A5045617170 @default.
• W1965017201 creator A5081145616 @default.
• W1965017201 date "2014-05-08" @default.
• W1965017201 modified "2023-09-27" @default.
• W1965017201 title "Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab" @default.
• W1965017201 cites W1849285658 @default.
• W1965017201 cites W1971267920 @default.
• W1965017201 cites W1978651690 @default.
• W1965017201 cites W1987326983 @default.
• W1965017201 cites W1989790390 @default.
• W1965017201 cites W1991584640 @default.
• W1965017201 cites W2040346137 @default.
• W1965017201 cites W2046030800 @default.
• W1965017201 cites W2059411043 @default.
• W1965017201 cites W2068822211 @default.
• W1965017201 cites W2078784420 @default.
• W1965017201 cites W2078915424 @default.
• W1965017201 cites W2093295719 @default.
• W1965017201 cites W2104337757 @default.
• W1965017201 cites W2108776415 @default.
• W1965017201 cites W2117984780 @default.
• W1965017201 cites W2128402413 @default.
• W1965017201 cites W2138222867 @default.
• W1965017201 cites W2146384083 @default.
• W1965017201 cites W2149908785 @default.
• W1965017201 cites W2151101674 @default.
• W1965017201 cites W2151809511 @default.
• W1965017201 cites W2154923670 @default.
• W1965017201 cites W2156677665 @default.
• W1965017201 cites W2157690591 @default.
• W1965017201 cites W2158077354 @default.
• W1965017201 cites W2159459001 @default.
• W1965017201 cites W2161791469 @default.
• W1965017201 cites W2318605753 @default.
• W1965017201 cites W4250006491 @default.
• W1965017201 doi "https://doi.org/10.1186/1471-2407-14-326" @default.
• W1965017201 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4037428" @default.
• W1965017201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24885187" @default.
• W1965017201 hasPublicationYear "2014" @default.
• W1965017201 type Work @default.
• W1965017201 sameAs 1965017201 @default.
• W1965017201 citedByCount "20" @default.
• W1965017201 countsByYear W19650172012015 @default.
• W1965017201 countsByYear W19650172012016 @default.
• W1965017201 countsByYear W19650172012017 @default.
• W1965017201 countsByYear W19650172012018 @default.
• W1965017201 countsByYear W19650172012019 @default.
• W1965017201 countsByYear W19650172012020 @default.
• W1965017201 countsByYear W19650172012021 @default.
• W1965017201 countsByYear W19650172012022 @default.
• W1965017201 countsByYear W19650172012023 @default.
• W1965017201 crossrefType "journal-article" @default.
• W1965017201 hasAuthorship W1965017201A5002120924 @default.
• W1965017201 hasAuthorship W1965017201A5011363732 @default.
• W1965017201 hasAuthorship W1965017201A5019302956 @default.
• W1965017201 hasAuthorship W1965017201A5021504145 @default.
• W1965017201 hasAuthorship W1965017201A5021514634 @default.
• W1965017201 hasAuthorship W1965017201A5027326018 @default.
• W1965017201 hasAuthorship W1965017201A5045617170 @default.
• W1965017201 hasAuthorship W1965017201A5081145616 @default.
• W1965017201 hasBestOaLocation W19650172011 @default.
• W1965017201 hasConcept C121608353 @default.
• W1965017201 hasConcept C126322002 @default.
• W1965017201 hasConcept C143998085 @default.
• W1965017201 hasConcept C204232928 @default.
• W1965017201 hasConcept C2775934546 @default.
• W1965017201 hasConcept C2776694085 @default.
• W1965017201 hasConcept C2777292972 @default.
• W1965017201 hasConcept C2778239845 @default.
• W1965017201 hasConcept C2778292576 @default.
• W1965017201 hasConcept C2779786085 @default.
• W1965017201 hasConcept C2780140570 @default.
• W1965017201 hasConcept C2781413609 @default.
• W1965017201 hasConcept C2781451048 @default.
• W1965017201 hasConcept C530470458 @default.
• W1965017201 hasConcept C71924100 @default.
• W1965017201 hasConceptScore W1965017201C121608353 @default.
• W1965017201 hasConceptScore W1965017201C126322002 @default.
• W1965017201 hasConceptScore W1965017201C143998085 @default.
• W1965017201 hasConceptScore W1965017201C204232928 @default.
• W1965017201 hasConceptScore W1965017201C2775934546 @default.
• W1965017201 hasConceptScore W1965017201C2776694085 @default.
• W1965017201 hasConceptScore W1965017201C2777292972 @default.
• W1965017201 hasConceptScore W1965017201C2778239845 @default.
• W1965017201 hasConceptScore W1965017201C2778292576 @default.
• W1965017201 hasConceptScore W1965017201C2779786085 @default.
• W1965017201 hasConceptScore W1965017201C2780140570 @default.
• W1965017201 hasConceptScore W1965017201C2781413609 @default.
• W1965017201 hasConceptScore W1965017201C2781451048 @default.
• W1965017201 hasConceptScore W1965017201C530470458 @default.
• W1965017201 hasConceptScore W1965017201C71924100 @default.
• W1965017201 hasIssue "1" @default.

• next